Outcomes and prognosis in advanced renal cell carcinoma.
Breakthroughs in understanding the pathogenesis of renal cell carcinoma have led to recent therapeutic advances in this disease. However, the US FDA approval of sunitinib and sorafenib (and soon temsirolimus) after successful Phase III trials must also be attributed to the work of clinical investigators over the past decade defining the outcomes and major prognostic factors in patients with advanced renal cell carcinoma. Those past studies have been critical in providing a context for the interpretation of future trials with novel agents, optimizing patient selection for specific therapeutic approaches and identifying appropriate variables for patient stratification on randomized trials. This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma.
Galsky
Matthew D
MD
Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA. matthew.galsky@usoncology.com
Vogelzang
Nicholas J
NJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome
D000970:Antineoplastic Agents